Atossa Therapeutics Approves Contingent Value Rights for Stockholders

What Happened
On September 29, 2026, Atossa Therapeutics, Inc. (ATOS) announced that its board of directors approved a plan to issue one contingent value right (CVR) for each share of the company’s common stock. The CVRs are intended to enable stockholders to share in a portion of any proceeds the company receives from the monetization of its first qualifying rare pediatric disease priority review voucher (PRV). The announcement was made public via a press release filed as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: September 29, 2026 (Form 8-K, Item 8.01).
• Action: Board approved issuing one contingent value right per share of common stock.
• Purpose: To allow stockholders to share in a portion of proceeds from monetizing the company’s first qualifying rare pediatric disease priority review voucher.
• Disclosure: Press release accompanying the 8-K is filed as Exhibit 99.1; the 8-K does not disclose CVR financial terms, timing, or the portion to be shared.

Why It Matters
This action notifies investors that Atossa intends to pass some potential upside from a PRV monetization directly to current stockholders via CVRs. The filing does not yet provide material details—such as how much of any proceeds will be shared, when monetization might occur, or the mechanics and timing of CVR payments—so the market impact is uncertain until further disclosures. Investors should watch for subsequent filings or press releases that describe the CVR terms and any related monetization events.